| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | PD-0332991 | FIMM | pan-cancer | AAC | 0.34 | 0.03 |
| mRNA | SB-225002 | CTRPv2 | pan-cancer | AAC | 0.07 | 0.03 |
| mRNA | MST-312 | CTRPv2 | pan-cancer | AAC | 0.079 | 0.03 |
| mRNA | GDC-0941 | GDSC1000 | pan-cancer | AAC | 0.08 | 0.03 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.077 | 0.03 |
| mRNA | ceranib-2 | CTRPv2 | pan-cancer | AAC | 0.074 | 0.03 |
| mRNA | SB-743921 | CTRPv2 | pan-cancer | AAC | 0.074 | 0.03 |
| mRNA | BRD-K71935468 | CTRPv2 | pan-cancer | AAC | -0.086 | 0.04 |
| mRNA | Crizotinib | FIMM | pan-cancer | AAC | 0.36 | 0.04 |
| mRNA | AZD6244 | FIMM | pan-cancer | AAC | 0.36 | 0.04 |